DNA repair systems in malignant mesothelioma

Cancer Letters

Volumn 312, Issue 2, 2011, Pages 143-149

  Toumpanakis, Dimitrios ^a   Theocharis, Stamatios E ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Asbestos; DNA repair; Gene expression; Malignant mesothelioma; Polymorphisms

Indexed keywords

CYCLINE; DNA (APURINIC OR APYRIMIDINIC SITE) LYASE; DNA GLYCOSYLTRANSFERASE; FLAP ENDONUCLEASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; REACTIVE OXYGEN METABOLITE; XRCC1 PROTEIN;

ALKYLATION; CANCER THERAPY; CARCINOGENESIS; DEAMINATION; DNA DAMAGE; DNA REPAIR; DNA SYNTHESIS; ENZYME ACTIVITY; EXCISION REPAIR; GENE EXPRESSION; GENE EXPRESSION SYSTEM; GENE MUTATION; GENETIC CODE; HOMOLOGOUS RECOMBINATION; HUMAN; HYDROXYLATION; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT MESOTHELIOMA; METHYLATION; MISMATCH REPAIR; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN TARGETING; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE STRANDED DNA BREAK;

EID: 80053969591     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.08.021     Document Type: Review

References (84)

1. Robinson B.W., Lake R.A. Advances in malignant mesothelioma. New Engl. J. Med. 2005, 353:1591-1603.
2. Robinson B.W., Musk A.W., Lake R.A. Malignant mesothelioma. Lancet 2005, 366:397-408.
3. Scherpereel A., Astoul P., Baas P., Berghmans T., Clayson H., de Vuyst P., Dienemann H., Galateau-Salle F., Hennequin C., Hillerdal G., Le Pechoux C., Mutti L., Pairon J.C., Stahel R., van Houtte P., van Meerbeeck J., Waller D., Weder W. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur. Respir. J. 2010, 35:479-495.
4. Heintz N.H., Janssen-Heininger Y.M., Mossman B.T. Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways. Am. J. Respir. Cell Mol. Biol. 2010, 42:133-139.
5. Choe N., Tanaka S., Kagan E. Asbestos fibers and interleukin-1 upregulate the formation of reactive nitrogen species in rat pleural mesothelial cells. Am. J. Respir. Cell Mol. Biol. 1998, 19:226-236.
6. Hussain S.P., Harris C.C. Inflammation and cancer: an ancient link with novel potentials. Int. J. Cancer 2007, 121:2373-2380.
7. Hoeijmakers J.H. Genome maintenance mechanisms for preventing cancer. Nature 2001, 411:366-374.
8. Loeb L.A., Loeb K.R., Anderson J.P. Multiple mutations and cancer. Proc. Natl Acad. Sci. USA 2003, 100:776-781.
9. Stratton M.R., Campbell P.J., Futreal P.A. The cancer genome. Nature 2009, 458:719-724.
10. Helleday T., Petermann E., Lundin C., Hodgson B., Sharma R.A. DNA repair pathways as targets for cancer therapy. Nat. Rev. Cancer 2008, 8:193-204.
11. Jackson S.P., Bartek J. The DNA-damage response in human biology and disease. Nature 2009, 461:1071-1078.
12. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., Santarosa M., Dillon K.J., Hickson I., Knights C., Martin N.M., Jackson S.P., Smith G.C., Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
13. Martin S.A., Lord C.J., Ashworth A. DNA repair deficiency as a therapeutic target in cancer. Curr. Opin. Genet. Dev. 2008, 18:80-86.
14. Lindahl T., Wood R.D. Quality control by DNA repair. Science 1999, 286:1897-1905.
15. Gatzidou E., Michailidi C., Tseleni-Balafouta S., Theocharis S. An epitome of DNA repair related genes and mechanisms in thyroid carcinoma. Cancer Lett. 2010, 290:139-147.
16. Lindahl T. Suppression of spontaneous mutagenesis in human cells by DNA base excision-repair. Mutat. Res. 2000, 462:129-135.
17. Krokan H.E., Nilsen H., Skorpen F., Otterlei M., Slupphaug G. Base excision repair of DNA in mammalian cells. FEBS Lett. 2000, 476:73-77.
18. Hegde M.L., Hazra T.K., Mitra S. Early steps in the DNA base excision/single-strand interruption repair pathway in mammalian cells. Cell Res. 2008, 18:27-47.
19. Upadhyay D., Kamp D.W. Asbestos-induced pulmonary toxicity: role of DNA damage and apoptosis. Exp. Biol. Med. (Maywood.) 2003, 228:650-659.
20. Jaurand M.C. Mechanisms of fiber-induced genotoxicity. Environ. Health Perspect. 1997, 105(Suppl. 5):1073-1084.
21. Chen Q., Marsh J., Ames B., Mossman B. Detection of 8-oxo-2'-deoxyguanosine, a marker of oxidative DNA damage, in culture medium from human mesothelial cells exposed to crocidolite asbestos. Carcinogenesis 1996, 17:2525-2527.
22. Unfried K., Schurkes C., Abel J. Distinct spectrum of mutations induced by crocidolite asbestos: clue for 8-hydroxydeoxyguanosine-dependent mutagenesis in vivo. Cancer Res. 2002, 62:99-104.
23. Fortini P., Pascucci B., Parlanti E., D'Errico M., Simonelli V., Dogliotti E. 8-Oxoguanine DNA damage: at the crossroad of alternative repair pathways. Mutat. Res. 2003, 531:127-139.
24. Ollikainen T., Linnainmaa K., Kinnula V.L. DNA single strand breaks induced by asbestos fibers in human pleural mesothelial cells in vitro. Environ. Mol. Mutagen. 1999, 33:153-160.
25. Dianzani I., Gibello L., Biava A., Giordano M., Bertolotti M., Betti M., Ferrante D., Guarrera S., Betta G.P., Mirabelli D., Matullo G., Magnani C. Polymorphisms in DNA repair genes as risk factors for asbestos-related malignant mesothelioma in a general population study. Mutat. Res. 2006, 599:124-134.
26. Caldecott K.W. XRCC1 and DNA strand break repair. DNA Repair (Amst) 2003, 2:955-969.
27. Monaco R., Rosal R., Dolan M.A., Pincus M.R., Brandt-Rauf P.W. Conformational effects of a common codon 399 polymorphism on the BRCT1 domain of the XRCC1 protein. Protein J. 2007, 26:541-546.
28. Taylor R.M., Thistlethwaite A., Caldecott K.W. Central role for the XRCC1 BRCT I domain in mammalian DNA single-strand break repair. Mol. Cell. Biol. 2002, 22:2556-2563.
29. Ladiges W., Wiley J., MacAuley A. Polymorphisms in the DNA repair gene XRCC1 and age-related disease. Mech. Ageing Dev. 2003, 124:27-32.
30. Betti M., Ferrante D., Padoan M., Guarrera S., Giordano M., Aspesi A., Mirabelli D., Casadio C., Ardissone F., Ruffini E., Betta P.G., Libener R., Guaschino R., Matullo G., Piccolini E., Magnani C., Dianzani I. XRCC1 and ERCC1 variants modify malignant mesothelioma risk: a case-control study. Mutat. Res. 2011, 708:11-20.
31. Gemignani F., Neri M., Bottari F., Barale R., Canessa P.A., Canzian F., Ceppi M., Spitaleri I., Cipollini M., Ivaldi G.P., Mencoboni M., Scaruffi P., Tonini G.P., Ugolini D., Mutti L., Bonassi S., Landi S. Risk of malignant pleural mesothelioma and polymorphisms in genes involved in the genome stability and xenobiotics metabolism. Mutat. Res. 2009, 671:76-83.
32. Fung H., Kow Y.W., Van Houten B., Taatjes D.J., Hatahet Z., Janssen Y.M., Vacek P., Faux S.P., Mossman B.T. Asbestos increases mammalian AP-endonuclease gene expression, protein levels, and enzyme activity in mesothelial cells. Cancer Res. 1998, 58:189-194.
33. Daviet S., Couve-Privat S., Gros L., Shinozuka K., Ide H., Saparbaev M., Ishchenko A.A. Major oxidative products of cytosine are substrates for the nucleotide incision repair pathway. DNA Repair (Amst) 2007, 6:8-18.
34. Hu J.J., Smith T.R., Miller M.S., Lohman K., Case L.D. Genetic regulation of ionizing radiation sensitivity and breast cancer risk. Environ. Mol. Mutagen. 2002, 39:208-215.
35. Yamane A., Kohno T., Ito K., Sunaga N., Aoki K., Yoshimura K., Murakami H., Nojima Y., Yokota J. Differential ability of polymorphic OGG1 proteins to suppress mutagenesis induced by 8-hydroxyguanine in human cell in vivo. Carcinogenesis 2004, 25:1689-1694.
36. Taguchi T., Jhanwar S.C., Siegfried J.M., Keller S.M., Testa J.R. Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma. Cancer Res. 1993, 53:4349-4355.
37. Neragi-Miandoab S., Sugarbaker D.J. Chromosomal deletion in patients with malignant pleural mesothelioma. Interact. Cardiovasc. Thorac. Surg. 2009, 9:42-44.
38. Yang H., Rivera Z., Jube S., Nasu M., Bertino P., Goparaju C., Franzoso G., Lotze M.T., Krausz T., Pass H.I., Bianchi M.E., Carbone M. Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc. Natl. Acad. Sci. USA 2010, 107:12611-12616.
39. Broaddus V.C., Yang L., Scavo L.M., Ernst J.D., Boylan A.M. Asbestos induces apoptosis of human and rabbit pleural mesothelial cells via reactive oxygen species. J. Clin. Invest. 1996, 98:2050-2059.
40. Ollikainen T., Puhakka A., Kahlos K., Linnainmaa K., Kinnula V.L. Modulation of cell and DNA damage by poly(ADP)ribose polymerase in lung cells exposed to H(2)O(2) or asbestos fibres. Mutat. Res. 2000, 470:77-84.
41. Dong H.Y., Buard A., Levy F., Renier A., Laval F., Jaurand M.C. Synthesis of poly(ADP-ribose) in asbestos treated rat pleural mesothelial cells in culture. Mutat. Res. 1995, 331:197-204.
42. Roe O.D., Anderssen E., Sandeck H., Christensen T., Larsson E., Lundgren S. Malignant pleural mesothelioma: genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets. Lung Cancer 2010, 67:57-68.
43. Krokan H.E., Standal R., Slupphaug G. DNA glycosylases in the base excision repair of DNA. Biochem. J. 1997, 325(Pt. 1):1-16.
44. Singhal S., Wiewrodt R., Malden L.D., Amin K.M., Matzie K., Friedberg J., Kucharczuk J.C., Litzky L.A., Johnson S.W., Kaiser L.R., Albelda S.M. Gene expression profiling of malignant mesothelioma. Clin. Cancer Res. 2003, 9:3080-3097.
45. Peterson C.L., Cote J. Cellular machineries for chromosomal DNA repair. Genes Dev. 2004, 18:602-616.
46. Volker M., Mone M.J., Karmakar P., van Hoffen A., Schul W., Vermeulen W., Hoeijmakers J.H., van Driel R., van Zeeland A.A., Mullenders L.H. Sequential assembly of the nucleotide excision repair factors in vivo. Mol. Cell 2001, 8:213-224.
47. Dip R., Camenisch U., Naegeli H. Mechanisms of DNA damage recognition and strand discrimination in human nucleotide excision repair. DNA Repair (Amst) 2004, 3:1409-1423.
48. Mitchell J.R., Hoeijmakers J.H., Niedernhofer L.J. Divide and conquer: nucleotide excision repair battles cancer and ageing. Curr. Opin. Cell Biol. 2003, 15:232-240.
49. Bergstralh D.T., Sekelsky J. Interstrand crosslink repair: can XPF-ERCC1 be let off the hook?. Trends Genet. 2008, 24:70-76.
50. Gao R., Reece K., Sissung T., Reed E., Price D.K., Figg W.D. The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivity. Mutat. Res. 2011, 708:21-27.
51. Kalikaki A., Kanaki M., Vassalou H., Souglakos J., Voutsina A., Georgoulias V., Mavroudis D. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin. Lung Cancer 2009, 10:118-123.
52. Dusinska M., Dzupinkova Z., Wsolova L., Harrington V., Collins A.R. Possible involvement of XPA in repair of oxidative DNA damage deduced from analysis of damage, repair and genotype in a human population stud. Mutagenesis 2006, 21:205-211.
53. Wu X., Zhao H., Wei Q., Amos C.I., Zhang K., Guo Z., Qiao Y., Hong W.K., Spitz M.R. XPA polymorphism associated with reduced lung cancer risk and a modulating effect on nucleotide excision repair capacity. Carcinogenesis 2003, 24:505-509.
54. Park J.Y., Park S.H., Choi J.E., Lee S.Y., Jeon H.S., Cha S.I., Kim C.H., Park J.H., Kam S., Park R.W., Kim I.S., Jung T.H. Polymorphisms of the DNA repair gene xeroderma pigmentosum group A and risk of primary lung cancer. Cancer Epidemiol. Biomarkers Prev. 2002, 11:993-997.
55. Li G.M. Mechanisms and functions of DNA mismatch repair. Cell Res. 2008, 18:85-98.
56. Harfe B.D., Jinks-Robertson S. DNA mismatch repair and genetic instability. Annu. Rev. Genet. 2000, 34:359-399.
57. Khanna K.K., Jackson S.P. DNA double-strand breaks: signaling, repair and the cancer connection. Nat. Genet. 2001, 27:247-254.
58. Thompson L.H., Schild D. Recombinational DNA repair and human disease. Mutat. Res. 2002, 509:49-78.
59. Shrivastav M., De Haro L.P., Nickoloff J.A. Regulation of DNA double-strand break repair pathway choice. Cell Res. 2008, 18:134-147.
60. San Filippo J., Sung P., Klein H. Mechanism of eukaryotic homologous recombination. Annu. Rev. Biochem. 2008, 77:229-257.
61. Lieber M.R. The mechanism of human nonhomologous DNA end joining. J. Biol. Chem. 2008, 283:1-5.
62. Lieber M.R. The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu. Rev. Biochem. 2010, 79:181-211.
63. Balsara B.R., Bell D.W., Sonoda G., De Rienzo A., Du M.S., Jhanwar S.C., Testa J.R. Comparative genomic hybridization and loss of heterozygosity analyses identify a common region of deletion at 15q11.1-15 in human malignant mesothelioma. Cancer Res. 1999, 59:450-454.
64. Shukla A., Hillegass J.M., MacPherson M.B., Beuschel S.L., Vacek P.M., Pass H.I., Carbone M., Testa J.R., Mossman B.T. Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin. Mol. Cancer 2010, 9:314.
65. Patel K.J., Joenje H. Fanconi anemia and DNA replication repair. DNA Repair (Amst) 2007, 6:885-890.
66. D'Andrea A.D., Grompe M. The Fanconi anaemia/BRCA pathway. Nat. Rev. Cancer 2003, 3:23-34.
67. Mor O., Yaron P., Huszar M., Yellin A., Jakobovitz O., Brok-Simoni F., Rechavi G., Reichert N. Absence of p53 mutations in malignant mesotheliomas. Am. J. Respir. Cell Mol. Biol. 1997, 16:9-13.
68. Testa J.R., Giordano A. SV40 and cell cycle perturbations in malignant mesothelioma. Semin. Cancer Biol. 2001, 11:31-38.
69. Cheng J.Q., Jhanwar S.C., Klein W.M., Bell D.W., Lee W.C., Altomare D.A., Nobori T., Olopade O.I., Buckler A.J., Testa J.R. P16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res. 1994, 54:5547-5551.
70. Altomare D.A., Menges C.W., Xu J., Pei J., Zhang L., Tadevosyan A., Neumann-Domer E., Liu Z., Carbone M., Chudoba I., Klein-Szanto A.J., Testa J.R. Losses of both products of the cdkn2a/arf locus contribute to asbestos-induced mesothelioma development and cooperate to accelerate tumorigenesis. PLoS ONE 2011, 6:e18828.
71. Kettunen E., Nissen A.M., Ollikainen T., Taavitsainen M., Tapper J., Mattson K., Linnainmaa K., Knuutila S., El Rifai W. Gene expression profiling of malignant mesothelioma cell lines: cDNA array study. Int. J. Cancer 2001, 91:492-496.
72. Sugarbaker D.J., Richards W.G., Gordon G.J., Dong L., De Rienzo A., Maulik G., Glickman J.N., Chirieac L.R., Hartman M.L., Taillon B.E., Du L., Bouffard P., Kingsmore S.F., Miller N.A., Farmer A.D., Jensen R.V., Gullans S.R., Bueno R. Transcriptome sequencing of malignant pleural mesothelioma tumors. Proc. Natl. Acad. Sci. USA 2008, 105:3521-3526.
73. Esteller M., Herman J.G. Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer. Oncogene 2004, 23:1-8.
74. Lehmann A.R. Replication of damaged DNA by translesion synthesis in human cells. FEBS Lett. 2005, 579:873-876.
75. Watts G.S., Pieper R.O., Costello J.F., Peng Y.M., Dalton W.S., Futscher B.W. Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol. Cell. Biol. 1997, 17:5612-5619.
76. Esteller M., Hamilton S.R., Burger P.C., Baylin S.B., Herman J.G. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999, 59:793-797.
77. Tsou J.A., Galler J.S., Wali A., Ye W., Siegmund K.D., Groshen S., Laird P.W., Turla S., Koss M.N., Pass H.I., Laird-Offringa I.A. DNA methylation profile of 28 potential marker loci in malignant mesothelioma. Lung Cancer 2007, 58:220-230.
78. Kristensen L.S., Nielsen H.M., Hager H., Hansen L.L. Methylation of MGMT in malignant pleural mesothelioma occurs in a subset of patients and is associated with the T allele of the rs16906252 MGMT promoter SNP. Lung Cancer 2011, 71:130-136.
79. Ogino S., Hazra A., Tranah G.J., Kirkner G.J., Kawasaki T., Nosho K., Ohnishi M., Suemoto Y., Meyerhardt J.A., Hunter D.J., Fuchs C.S. MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer. Carcinogenesis 2007, 28:1985-1990.
80. Shaheen M., Shanmugam I., Hromas R. The role of PCNA posttranslational modifications in translesion synthesis. J. Nucleic Acids 2010, 2010.
81. Nojima K., Hochegger H., Saberi A., Fukushima T., Kikuchi K., Yoshimura M., Orelli B.J., Bishop D.K., Hirano S., Ohzeki M., Ishiai M., Yamamoto K., Takata M., Arakawa H., Buerstedde J.M., Yamazoe M., Kawamoto T., Araki K., Takahashi J.A., Hashimoto N., Takeda S., Sonoda E. Multiple repair pathways mediate tolerance to chemotherapeutic cross-linking agents in vertebrate cells. Cancer Res. 2005, 65:11704-11711.
82. Moldovan G.L., Pfander B., Jentsch S. PCNA, the maestro of the replication fork. Cell 2007, 129:665-679.
83. Esposito V., Baldi A., De Luca A., Paciocco G., Groger A., Sgaramella G., Claudio P.P., Giordano G.G., Baldi F., Caputi M., Kaiser H., Giordano A. Role of PCNA in differentiating between malignant mesothelioma and mesothelial hyperplasia: prognostic considerations. Anticancer Res. 1997, 17:601-604.
84. Ramael M., Jacobs W., Weyler J., van Meerbeeck J., Bialasiewicz P., Van den B.J., Buysse C., Vermeire P., Van Marck E. Proliferation in malignant mesothelioma as determined by mitosis counts and immunoreactivity for proliferating cell nuclear antigen (PCNA). J. Pathol. 1994, 172:247-253.